A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
Completed · Phase 1 · NCT02966782
Conditions: Myelodysplastic Syndromes (MDS)
At a glance
- Research payments reported, 2025
- $14,672
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- AbbVie (with Celgene, Genentech, Inc.)
- Tested
- venetoclax (drug), azacitidine (drug)
- Dates
- Started 2017-03-07; completion 2023-04-05
- Results posted
- Not yet
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
From ClinicalTrials.gov, last updated 2023-05-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $14,672 in research payments for this study in 2025 (2 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Arizona $14,672
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.